Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 350Stomach Neoplasms 31Neoplasm Metastasis 30Breast Neoplasms, Male 25Neoplasms 16Inflammatory Breast Neoplasms 12Brain Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Adenocarcinoma 5Sarcoma 4Lung Neoplasms 4HER2-positive Breast Cancer 4Endometrial Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3HER2 Positive Breast Cancer 3Cardiotoxicity 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3

Interventions

Trastuzumab 1Paclitaxel 1HM781-36B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HER-2 Positive Advanced Gastric Cancer × Trastuzumab × Clear all
NCT01746771 2016-03-03

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Hanmi Pharmaceutical Company Limited

Phase 1/2 Completed
44 enrolled
Gastrointestinal

HER-2 Positive Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡